Jubilant Pharmova’s step down subsidiary -- Jubilant Biosys Innovative Research Services (JBIRSPL) has executed Shareholders’ Agreement and other transition agreements with Pierre Fabre SA, and its affiliate entities (PF), and subscribed to 80% equity capital in JASMIN, with remaining 20% equity capital retained by PF. Simultaneously, the acquisition of PF’s R&D Centre (including R&D Site and R&D activities) at Saint Julien, France by JASMIN stands successfully closed.
JASMIN is a company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS). On closure of transaction, name of JASMIN has been changed to ‘Jubilant Biosys France’ which is now a subsidiary of JBIRSPL.
JBIRSPL is a subsidiary of Jubilant Biosys, a wholly owned subsidiary of the company.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
